Clinical Trials Directory

Trials / Completed

CompletedNCT03935841

Metabolic Differences of an Oral and Intravenous Dose of 3-hydroxybutyrate (3-OHB).

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
8 (actual)
Sponsor
University of Aarhus · Academic / Other
Sex
Male
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

An open-labeled intervention study testing healthy, lean, and male volunteers on two separate occasions: 1. blood sampling after consuming 36 gram 3-Hydroxybutyrate (3-OHB) salt. 2. blood sampling while given a variable rate of 3-OHB salt intravenously to replicate the concentrations seen during oral consumption. The primary outcome is differences in insulin concentrations (incremental AUC) 180 minutes after 3-OHB consumed orally vs. intravenously. Secondary outcomes includes iAUC for other gastrointestinal hormones and substrates (Glucagon, GLP-1, GIP, glucose, and 3-OHB) Gastric emptying will be evaluated using 1500 mg Paracetamol consumption before each intervention day. Urine will be analyzed for ketone concentrations/excretion rates.

Detailed description

An open-labeled intervention study testing healthy, lean, and male volunteers on two separate occasions with at least 48 hours apart. 1. blood sampling after consuming 36 gram 3-Hydroxybutyrate (3-OHB) salt. 2. blood sampling while given a variable rate of 3-OHB salt intravenously to replicate the concentrations seen during oral consumption. The primary outcome is differences in insulin concentrations (incremental AUC) 180 minutes after 3-OHB consumed orally vs. intravenously. Secondary outcomes includes iAUC for other gastrointestinal hormones and substrates (Glucagon, GLP-1, GIP, glucose, and 3-OHB) Gastric emptying will be evaluated using 1500 mg Paracetamol consumption before each intervention day. Urine will be analyzed for ketone concentrations/excretion rates.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENT3-OHB salt (NaCl)36 gram 3-OHB salt diluted in 500 ml sterile water

Timeline

Start date
2019-06-07
Primary completion
2019-11-01
Completion
2020-03-01
First posted
2019-05-02
Last updated
2020-11-03

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT03935841. Inclusion in this directory is not an endorsement.